Material Event (Form 8-K)

Item 8.01 Other Events.

In response to recent investor inquiries regarding third-party postings concerning potential combination trials involving agenT-797, MiNK Therapeutics, Inc. (the "Company") is providing the following clarification:

The Company is actively engaged in discussions with multiple parties regarding potential combination trials involving agenT-797, its proprietary allogeneic iNKT cell therapy, as well as potential strategic minority investments in the Company. The Company believes these discussions reflect growing interest in the Company's platform, including its potential application in areas of significant unmet medical need such as critical illness.

The Company has not publicly disclosed any binding arrangements with respect to potential combination trials or strategic investments.